Aegerion developed and commercialized innovative drugs for patients with rare diseases.
Aegerion went public on NASDAQ in 2010.
FDA Advisory Committee Recommends Approval of Lomitapide for Treatment of
Homozygous Familial Hypercholesterolemia (HoFH)
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), announces the pricing of its initial public offering of 5,000,000 shares of its common stock at $9.50 per share